<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02877277</url>
  </required_header>
  <id_info>
    <org_study_id>H-16022249</org_study_id>
    <nct_id>NCT02877277</nct_id>
  </id_info>
  <brief_title>Epigenetics, Vitamin C and Abnormal Hematopoiesis - Pilot Study</brief_title>
  <acronym>EVITA-Pilot</acronym>
  <official_title>Restoring Physiological Vitamin C Levels to the Normal Range: Influence on Epigenetic Regulation in Normal and Malignant Hematopoiesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates whether vitamin C improves responses to epigenetic therapy with DNMTis.
      Half of the patients will receive vitamin C and DNMTi while the other half will receive
      placebo and DNMTi.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recently, it was documented that hematological cancer patients with myelodysplastic syndrome
      (MDS) or acute myeloid leukemia (AML) exhibited severe vitamin C deficiency. Vitamin C is an
      essential co-factor for ten-eleven translocation (TET) enzymes, which initiate DNA
      demethylation through oxidation of 5-methylcytosine (mC) to 5-hydroxy-methylcytosine (hmC).
      In-vitro studies show that vitamin C at physiological doses added to DNA methyltransferase
      inhibitors (DNMTis), induce a synergistic inhibition of cell proliferation and enhanced
      apoptosis. These effects are mediated via a viral mimicry response recently associated with
      cancer stem-like cell death and enhanced immune signals including increased expression of
      bi-directionally transcribed endogenous retrovirus (ERV) transcripts, increased presence of
      cytosolic double stranded RNAs, and activation of an interferon inducing cellular response to
      these transcripts. Data suggest that correction of vitamin C deficiency may improve responses
      to epigenetic therapy with DNMTis. In the EVITA pilot study, the investigators include
      MDS/AML patients and explore the potential role of restoring vitamin C within the normal
      physiological range in treatment of hematological cancer with DNMTis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall 5-hmC/5-mC ratio</measure>
    <time_frame>Change from baseline to day 84</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall lysine methylation levels</measure>
    <time_frame>Change from baseline to day 84</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>5-hmC/5-mC ratio at regulatory genomic regions of genes involved in hematopoietic development</measure>
    <time_frame>Change from baseline to day 84</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation of 5-hmC/5-mC at regulatory regions of ERVs</measure>
    <time_frame>Change from baseline to day 84</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Aberrant histone methylation associated with hematopoietic development</measure>
    <time_frame>Change from baseline to day 84</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Aberrant histone methylation associated with ERVs</measure>
    <time_frame>Change from baseline to day 84</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Expression levels of ERVs</measure>
    <time_frame>Change from baseline to day 84</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Activity of the viral defense pathway measured by RNA and protein expression</measure>
    <time_frame>Change from baseline to day 84</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ERV specific T-cell recognition in vivo</measure>
    <time_frame>Change from baseline to day 84</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Vitamin C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral intake of vitamin C tablet (500 mg) daily for 56 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral intake of placebo tablet daily for 56 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>Oral intake of vitamin C tablet (500 mg) daily for 56 days</description>
    <arm_group_label>Vitamin C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral intake of placebo tablet daily for 56 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  MDS/AML patient in treatment with DNMTi

        Exclusion Criteria:

          -  Intake of vitamin C as a dietary supplement including multivitamin

          -  Non-compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kirsten Grønbæk, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kirsten Grønbæk, Professor</last_name>
    <phone>+45 35 45 60 86</phone>
    <email>kirsten.groenbaek@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>København Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Grønbæk, Professor</last_name>
      <phone>+45 35 45 60 86</phone>
      <email>kirsten.groenbaek@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Laurine BS Harsløf, PhD</last_name>
      <phone>+45 35 45 60 80</phone>
      <email>laurine.bente.schram.harsloef@regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Kirsten Grønbæk, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas D Ørskov, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Linn ME Gillberg, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jakob W Hansen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2016</study_first_submitted>
  <study_first_submitted_qc>August 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2016</study_first_posted>
  <last_update_submitted>September 26, 2017</last_update_submitted>
  <last_update_submitted_qc>September 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Kirsten Grønbæk</investigator_full_name>
    <investigator_title>Professor, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

